Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Vulvar Cancer: early-phase trial registry
8 of 18 indexed Vulvar Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 8 currently recruiting · #953 of 28,707 conditions by registered trial count
Vulvar Cancer: 18 US clinical trials tracked, 8 recruiting.
Vulvar Cancer is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition vulvar-cancer
OPEN 8 | RECR 44% | LATE 1 | EARLY 6 | RANK #953 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Vulvar Cancer lists 8 open slots (44% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Vulvar Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Vulvar Cancer is recruiting below its size-band peers.
8 of 18 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Vulvar Cancer research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 18 trials (16.7%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Vulvar Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 18 trials that report a genuine target (sentinel values excluded). 12 of those (66.7%) plan for fewer than 100 participants.
-
Vulvar Cancer research is mostly interventional.
16 interventional and 2 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
NCT00005095
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Northwestern University
NCT05743517
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
University Medical Center Groningen
NCT05076942
Serial MRI Scans During Radiation Therapy
Dana-Farber Cancer Institute
NCT04188535
ASk Questions in GYnecologic Oncology (ASQ-GYO)
Ira Winer
NCT06339827
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
University of Utah
NCT05979610
Image-Guided Gynecologic Brachytherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02993900
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06677190
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
Duke University
NCT03403465
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Cancer Institute (NCI)
NCT04708470
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Massachusetts General Hospital
NCT04430699
Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer
Memorial Sloan Kettering Cancer Center
NCT06127836
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
Gynecologic Oncology Group
NCT00003325
Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer
Memorial Sloan Kettering Cancer Center
NCT05255393
Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients.
Women and Infants Hospital of Rhode Island
NCT00315159
Interventions to Decrease Financial Toxicity
University of Alabama at Birmingham
NCT05939440
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
Emory University
NCT01526486
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Memorial Sloan Kettering Cancer Center
NCT00504023
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Vulvar Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Vulvar Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Vulvar Cancer page
18 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Vulvar Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Vulvar Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vulvar Cancer condition card totals 18 registered trials; most-linked intervention Cisplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.